Dermira Company Profile (NASDAQ:DERM)

About Dermira (NASDAQ:DERM)

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DERM
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.14 billion
  • Outstanding Shares: 41,521,000
Average Prices:
  • 50 Day Moving Avg: $31.11
  • 200 Day Moving Avg: $31.92
  • 52 Week Range: $25.63 - $38.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.83
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $23.65 million
  • Price / Sales: 48.03
  • Book Value: $9.76 per share
  • Price / Book: 2.80
  • EBIDTA: ($91,810,000.00)
  • Return on Equity: -51.30%
  • Return on Assets: -42.90%
  • Current Ratio: 9.53%
  • Quick Ratio: 9.53%
  • Average Volume: 482,164 shs.
  • Beta: 0.8
  • Short Ratio: 4.12

Frequently Asked Questions for Dermira (NASDAQ:DERM)

What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

How were Dermira's earnings last quarter?

Dermira Inc (NASDAQ:DERM) issued its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.93) by $0.72. The firm earned $22.47 million during the quarter. View Dermira's Earnings History.

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

8 brokers have issued 1 year target prices for Dermira's stock. Their predictions range from $40.00 to $47.00. On average, they expect Dermira's share price to reach $43.80 in the next twelve months. View Analyst Ratings for Dermira.

What are analysts saying about Dermira stock?

Here are some recent quotes from research analysts about Dermira stock:

  • 1. Guggenheim analysts commented, "4Q16 results underscore that DERM continues to advance its pipeline of drugs that address large unmet needs in dermatology. Positive clinical data for DRM01 and DRM04 as well as solid execution in 4Q16, give us greater conviction in our positive investment thesis for the stock. We continue to think stock price appreciation will be driven by upward consensus earnings revisions to DERM's pipeline drug sales. We also view DERM as an attractive company in a consolidating industry." (3/2/2017)
  • 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (1/10/2017)

Are investors shorting Dermira?

Dermira saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 3,553,868 shares, an increase of 66.8% from the April 28th total of 2,130,184 shares. Based on an average daily volume of 906,401 shares, the short-interest ratio is presently 3.9 days. Approximately 12.4% of the company's shares are sold short.

Who are some of Dermira's key competitors?

Who owns Dermira stock?

Dermira's stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (9.83%), BlackRock Inc. (9.51%), FMR LLC (9.02%), TimesSquare Capital Management LLC (7.26%), Jennison Associates LLC (6.32%) and Eagle Asset Management Inc. (3.68%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.

Who sold Dermira stock? Who is selling Dermira stock?

Dermira's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Jennison Associates LLC, Blue Jay Capital Management LLC, Teachers Advisors LLC, JPMorgan Chase & Co., Nicholas Investment Partners LP and Century Capital Management LLC. Company insiders that have sold Dermira stock in the last year include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo. View Insider Buying and Selling for Dermira.

Who bought Dermira stock? Who is buying Dermira stock?

Dermira's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Jana Partners LLC, Vanguard Group Inc., Granite Investment Partners LLC, Foresite Capital Management II LLC and Foresite Capital Management III LLC. View Insider Buying and Selling for Dermira.

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dermira stock cost?

One share of Dermira stock can currently be purchased for approximately $27.36.

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (?)
Ratings Breakdown: 3 Sell Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $43.80 (60.09% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017MizuhoLower Price TargetBuy -> Buy$42.00 -> $40.00LowView Rating Details
3/16/2017Raymond James Financial, Inc.Initiated CoverageUnderperform -> UnderperformHighView Rating Details
3/15/2017Citigroup IncInitiated CoverageUnderperformHighView Rating Details
3/2/2017GuggenheimReiterated RatingBuy -> Positive$40.00N/AView Rating Details
1/3/2017SEB Equity ResearchReiterated RatingReduceN/AView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
10/3/2016Needham & Company LLCReiterated RatingPositive$46.00N/AView Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00N/AView Rating Details
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Dermira (NASDAQ:DERM)
Earnings by Quarter for Dermira (NASDAQ:DERM)
Earnings History by Quarter for Dermira (NASDAQ:DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q4 2016($0.93)($0.21)$22.47 millionViewListenView Earnings Details
11/7/2016Q316($0.72)($0.72)$0.12 millionViewN/AView Earnings Details
8/8/2016Q2($0.86)($0.89)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)$7.30 millionViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)$7.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dermira (NASDAQ:DERM)
2017 EPS Consensus Estimate: ($3.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.84)($0.84)($0.84)
Q2 20171($0.81)($0.81)($0.81)
Q3 20171($1.00)($1.00)($1.00)
Q4 20171($1.23)($1.23)($1.23)
(Data provided by Zacks Investment Research)


Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 17.30%
Institutional Ownership Percentage: 84.92%
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)
Insider Trades by Quarter for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Christopher M. GriffithSVPSell1,312$27.07$35,515.84View SEC Filing  
4/17/2017Christopher M. GriffithSVPSell1,303$33.97$44,262.91View SEC Filing  
4/3/2017Eugene A BauerInsiderSell2,500$33.53$83,825.00View SEC Filing  
4/3/2017Thomas G WiggansCEOSell8,000$33.49$267,920.00View SEC Filing  
4/3/2017William R RingoDirectorSell500$34.03$17,015.00View SEC Filing  
3/15/2017Christopher M. GriffithSVPSell1,303$35.79$46,634.37View SEC Filing  
3/1/2017Eugene A BauerInsiderSell2,500$33.61$84,025.00View SEC Filing  
3/1/2017Thomas G WiggansCEOSell11,000$33.54$368,940.00View SEC Filing  
3/1/2017William R RingoDirectorSell500$35.09$17,545.00View SEC Filing  
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Dermira (NASDAQ:DERM)
Latest Headlines for Dermira (NASDAQ:DERM)
DateHeadline logoDermira Inc (DERM) PT Lowered to $40.00 - May 27 at 12:58 AM logoDermira Inc (DERM) Given Average Rating of "Hold" by Brokerages - May 26 at 10:50 AM logoTeva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts - May 25 at 6:30 PM logoDermira Inc (DERM) Short Interest Up 2.9% in April - May 22 at 9:16 PM logoDERMIRA, INC. (DERM) - May 16 at 9:43 PM logoInsider Selling: Dermira Inc (DERM) SVP Sells 1,312 Shares of Stock - May 16 at 8:44 PM logoDermira Announces Closing of 3.00% Convertible Senior Notes Offering - May 16 at 4:42 PM logoDermira Inc (DERM) Expected to Earn Q2 2017 Earnings of ($0.81) Per Share - May 11 at 8:52 AM logoDermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes - May 10 at 9:51 PM logoHere's Why Dermira Fell as Much as 18.7% This Morning - May 10 at 4:51 PM logoFY2020 EPS Estimates for Dermira Inc (DERM) Cut by Analyst - May 10 at 3:38 PM logoDermira Announces Proposed Offering of $250 Million of Convertible Senior Notes - May 9 at 4:41 PM logoBRIEF-Dermira qtrly net loss per share, basic, diluted $ 0.79 - May 9 at 5:43 AM logoDermira Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 9 at 5:43 AM logoDermira reports 1Q loss - May 8 at 5:36 PM logoDermira Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 8 at 4:30 PM logoDermira (DERM) Earning Somewhat Favorable Media Coverage, Study Finds - May 1 at 5:44 PM logoDermira Inc (DERM) Given Consensus Rating of "Hold" by Analysts - May 1 at 2:24 PM logoDermira Inc (DERM) Expected to Announce Earnings of -$0.86 Per Share - May 1 at 10:04 AM logoDermira (DERM) Earning Somewhat Negative News Coverage, Report Finds - April 28 at 10:26 AM logoDermira (DERM) Given Coverage Optimism Score of 0.12 - April 25 at 7:30 PM logoDermira (DERM) Getting Favorable News Coverage, AlphaOne Reports - April 22 at 2:49 PM logoDermira, Inc. – Value Analysis (NASDAQ:DERM) : April 20, 2017 - April 20 at 4:49 PM logoDermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : April 19, 2017 - April 19 at 12:31 PM logoDermira (DERM) Getting Positive News Coverage, Study Shows - April 19 at 10:04 AM logoInsider Selling: Dermira Inc (DERM) SVP Sells 1,303 Shares of Stock - April 18 at 10:59 PM logoDermira (DERM) Earns Media Impact Rating of 0.30 - April 16 at 9:08 AM logoDermira Inc (DERM) Expected to Post Earnings of -$0.86 Per Share - April 10 at 12:13 PM logoDermira Inc (DERM) Now Covered by Analysts at Mizuho - April 5 at 10:22 AM logoInsider Selling: Dermira Inc (DERM) Director Sells 500 Shares of Stock - April 4 at 9:19 PM logoInsider Selling: Dermira Inc (DERM) Insider Sells 2,500 Shares of Stock - April 4 at 8:58 PM logoDermira Inc (DERM) CEO Sells $267,920.00 in Stock - April 4 at 8:37 PM logoInteresting DERM Put And Call Options For December 15th - April 3 at 5:06 PM logoCoverage initiated on Dermira by Mizuho - March 31 at 4:49 PM logoLeerink Swann Comments on Dermira Inc's Q1 2017 Earnings (DERM) - March 31 at 12:14 PM logoMizuho Initiates Coverage on Dermira Inc (DERM) - March 30 at 8:54 PM logoDermira to Present at Needham 16th Annual Healthcare Conference - March 28 at 4:25 PM logoFoamix's acne drug misses main goal in key study, shares slump - March 27 at 12:13 PM logoDermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting - GlobeNewswire (press release) - March 21 at 9:58 PM logoDermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting - March 21 at 8:06 AM logoDermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting - March 17 at 5:02 PM logoCoverage initiated on Dermira by Raymond James - March 16 at 6:06 PM logoCommit To Buy Dermira At $30, Earn 15% Annualized Using Options - March 15 at 5:06 PM logoDermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - March 7 at 4:39 PM logo8:25 am Dermira announces the co presented new data in primary axillary hyperhidrosis & acne at American Academy of Dermatology 2017 Annual Meeting - March 5 at 11:59 AM logoNew CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting - March 4 at 5:05 PM logoDERMIRA, INC. Financials - March 4 at 5:05 PM logoDermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting - March 3 at 4:46 PM logoDERM Prices Offering At $33.70/Share - March 2 at 10:01 PM logoDermira to Present at Cowen and Company 37th Annual Health Care Conference - March 2 at 4:57 PM



Dermira (DERM) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff